Robert E. Burrier, Ph.D.
Dr. Burrier is a career technology executive with experience in pharmaceutical research, ‘biosupplier’ product development, and biotech services. While working in pharma, he participated and led programs resulting in drugs currently on the market including Zetia, Vytorin, and others. He is very experienced in assays and paradigms used for drug discovery having participated in over 150 drug discovery programs while working for Schering-Plough, Eli Lilly, GelTex, and Genzyme. In the Biosupplier arena, Dr. Burrier led teams to innovate on an ongoing basis in the areas of cell biology, cell media development, assay development, and workflow improvements with companies including Invitrogen, and EMD Millipore (Merck). The markets around which these programs were based include academic and industrial cell biology research, stem cells and regenerative medicine, as well as biotherapeutic protein production. Dr. Burrier joined Stemina to bring his expertise of cell biology, assay development, scientific operations, program management, and organizational effectiveness to facilitate success and to continue to fulfill his interest of continually improving human health.
Learn more about Dr. Burrier’s research at PubMed.
David G. Amaral, Ph.D.
David G. Amaral, Ph.D is a Professor of Psychiatry and Behavioral Sciences at the University of California, Davis. He is the Research Director and Beneto Foundation Chair at the M.I.N.D. Institute. (Medical Investigation of Neurodevelopmental Disorders). Dr. Amaral was named the Beneto Foundation Chair and Research Director of the M.I.N.D. Institute in 1998. The M.I.N.D. Institute is dedicated to understanding the biological bases of autism and other neurodevelopmental disorders with the goal of developing preventative measures and innovative treatments. Dr. Amaral was a founding member of the M.I.N.D. Institute and has been charged with guiding the overall research mission of the Institute. As Research Director at the M.I.N.D. Institute, he is currently coordinating a comprehensive and multidisciplinary analysis of children with autism called the Autism Phenome Project to define biomedical characteristics of different types of autism. This project will lead to more effective hypothesis driven research on the causes of each type of autism and ultimately to more effective treatments. Dr. Amaral received his BS from Northwestern University and his Ph.D from the University of Rochester Neuroscience and Psychology. He conducted postdoctoral research at the Department of Anatomy and Neurobiology at Washington University. He then spent 13 years at the Salk Institute for Biological Studies.
To learn more about Dr. Amaral, visit the UC Davis Mind Institute’s website.
Learn more about Dr. Amaral’s research at PubMed.
Oliver Fiehn, Ph.D.
Dr. Oliver Fiehn is a Professor at the University of California, Davis in the Department of Molecular and Cellular Biology and the Genome Center. He obtained his undergraduate degree in Chemistry from the Free University of Berlin, Germany and his Ph.D from the Technical University of Berlin, Germany. Subsequently, he joined the Max-Planck Institute of Molecular Plant Physiology, starting the field of plant metabolomics. He has published more than 100 papers in peer-reviewed journals and is a member of the board of the directors of the Metabolomics Society, and member of the editorial boards of several journals, among them the Rapid Communications in Mass Spectrometry. Dr. Fiehn’s main research field is mass spectrometry and its use for metabolite analysis, in conjunction with bioinformatics approaches to utilize metabolic data for plant and animal research. To learn more about Dr. Fiehn, please visit the UC-Davis website.
Learn more about Dr. Fiehn’s research at PubMed.
Steven Fischer received his bachelors in chemistry (1981) and masters in chemistry (1991) at California State University, Hayward. In 1986, he joined Agilent Technologies in Santa Clara (previously part of Hewlett-Packard Company) where he has designed and applied HPLC/MS instrumentation for analytical problems for 23 years. He has over 40 United States issued patents in the field of mass spectrometry and over 20 peer reviewed publications. He was the recipient of Agilent Technologies 2007 Bill Hewlett Award for outstanding instrument design innovation. He currently is Director of Omics Applications managing Agilent’s world wide metabolomics and proteomics program. His group works on developing solutions to the challenges of metabolomics, proteomics and integrated biology analysis.
To learn more about Mr. Fischer, visit the Agilent Technologies website.
Learn more about Mr. Fischer’s research at PubMed.
Minesh Mehta, MB, ChB
Dr. Mehta is an internationally recognized expert in human clinical drug trial strategy, design and execution and has managed national and international trials of all sizes including International Phase 3 trials. He was Professor in the Department of Human Oncology at the University of Wisconsin’s School of Medicine and Public Health from 2002-2010, including being the Program Leader of the Imaging and Radiation Sciences Program of the Paul P. Carbone Comprehensive Cancer Center (UWCCC). Dr. Mehta was Chairman of the Department of Human Oncology from 1997 to 2007. He has been a member of the Board of Directors of the American Society for Therapeutic Radiology and Oncology (ASTRO) since 2006 and Chair of the Radiation Therapy Oncology Group (RTOG) Brain Tumor Committee since 1998. From 1997 to 2001, he served as an ad-hoc member of the FDA’s Technology Assessment Committee and from 2001 to 2005, he served on and eventually Chaired the FDA Radiological Devices Panel. He has more than 400 publications to his credit, especially in the areas of radiation therapy and translational and clinical cancer research. Dr. Mehta obtained his medical degree at the University of Zambia in 1981 and commenced his residency there at the Ndola Central Hospital. He moved to the University of Wisconsin, Madison, in 1984 and completed his residency in radiation oncology in 1988 when he took up an Assistant Professorship in Human Oncology, was promoted to Associate Professor and became the Director of the Radiation Oncology Residency Training Program. After serving as Vice-Chairman and Interim Chairman, Dr. Mehta became Chair of Human Oncology and also a Professor in the Department of Neurological Surgery. Dr. Mehta has authored over 70 clinical protocols. From 2010-12, he served as Professor of Radiation Oncology and co-Director of the Solid Tumor Investigations Program at Northwestern University, Chicago. He is currently Professor of Radiation Oncology, Vice-Chair for Clinical Research at the University of Maryland, and Director of the Maryland Proton Treatment Center.
To learn more about Dr. Mehta, visit The University of Maryland School of Medicine website.
Learn more about Dr. Mehta’s research at PubMed.
G. Sitta Sittampalam, PhD
Dr. Sittampalam is a Senior Advisor to the Director and Project Manager in the division of Therapeutics for Rare & Neglected Diseases Program (TRND), which is part of the National Center for Advancing Translational Therapeutics (NCATS) at the NIH. His current responsibilities include multiple project and alliance management in TRND and NCATS, promoting promising drug candidates from academia for rare and neglected diseases to the clinic, and expanding The Learning Collaborative (TLC) concept developed at NCATS, The University of Kansas Cancer Center and the Leukemia Lymphoma Society. Dr. Sittampalam has over 23 years of experience in drug discovery and development in the pharmaceutical industry (Eli Lilly & Co, Indianapolis, IN), and served 4 years in academic drug discovery and high throughput screening as the Deputy Director of the Institute of Advancing Medical Innovations, and was a professor of Pharmacology, Toxicology & Therapeutics at the University of Kansas Cancer Center. Kansas City, KS (2007-2011). His current interests are in developing physiologically relevant 3D cellular models for cancer drug discovery and circulating tumor cells & cancer stem cells as biomarkers. He was a member of NIH RoadMap MLPCN Grants Review Panels (2005-2009) and has served on stem cell research grant review panels in Maryland (MSCRF) and California (CIRM). He is currently the Editor-in-Chief of the Assay Guidance Manual, sponsored by NCATS and NIMH and published as an e-Book on the NCBI website, a division of the National Library of Medicine, editorial board of the Journal of Biomolecular Sciences (2007-present) and the scientific advisory boards of Science Translational Medicine, Science Exchange Inc., and Stemina Biomarker Discovery, Inc.
Learn more about Dr. Sittampalam’s research at PubMed.